Blog
Wat is Regulatory Affairs in Pharma? Taken & Carrière
Regulatory Affairs is het vakgebied dat zich bezighoudt met de registratie en goedkeuring van geneesmiddelen en medische hulpmiddelen. Ontdek de taken, functies en hoe SIRE® Life Sciences RA-professionals plaatst in Nederland.
Read MoreWat is een GMP Consultant? Taken, Kwalificaties & Salaris
Een GMP consultant adviseert farmaceutische en biotech bedrijven over Good Manufacturing Practice. Ontdek de taken, kwalificaties, salaris en hoe SIRE® Life Sciences GMP-experts plaatst in Nederland.
Read MoreWat is Secondment in Life Sciences? Uitleg & Voordelen
Secondment in life sciences betekent dat een professional tijdelijk werkt bij een opdrachtgever terwijl hij of zij formeel in dienst blijft bij het detacheringsbureau. Ontdek hoe het werkt, de voordelen en het verschil met uitzenden.
Read MoreScaling Biotech Manufacturing in the Netherlands: Project Structures That Enable Growth
The Netherlands has managed to place itself subtly at the forefront of some of the biggest biotech clusters in Europe. Leiden Bio Science Park, Pivot Park, and Utrecht Science Park are witnessing an unprecedented rate of innovation in the country. The latest treatments are being taken a step further in clinical trials. The financial front…
Read MoreManaging Technology Transfers in Dutch Pharmaceutical Manufacturing Facilities
Technology Transfer Looks Straightforward on Paper. Reality Is Different. If you read most regulatory guidance, technology transfer in pharmaceutical manufacturing sounds fairly simple. A process is developed. The documentation is prepared. Another site reproduces the process. Done. At least, that’s how it often appears in theory. In practice, it rarely unfolds that neatly. At SIRE®…
Read MoreCost Control in GMP Projects: How Structured Project Consultancy Protects Budgets
A Conversation That we are Stuck With A few months ago, while we were speaking with someone managing a facility expansion for a biotechnology company here in the Netherlands. The project looked well organized. Budget approved. Timeline agreed. Engineering plans already signed off. Everything seemed fairly stable. Then things began to shift. A supplier updated…
Read MoreBuilding a PMO in the Netherlands Life Sciences Sector: When and Why It Matters
Building a PMO in the Netherlands Life Sciences Sector: When and Why It Matters Building a PMO in the Netherlands Life Sciences sector is increasingly essential for organizations managing complex innovation pipelines. At SIRE® Life Sciences, we’ve seen firsthand how companies juggling multiple R&D programs struggle with resource allocation, strategic alignment and project visibility challenges…
Read MoreHow Dutch Pharma Companies Can De-Risk CAPEX Projects Through Structured Consultancy Models
Why CAPEX Projects in Dutch Pharma Are Becoming Harder and What Companies are Doing About It A few months ago, we were speaking with someone leading a facility expansion project for a pharmaceutical company in the Netherlands. The conversation started the way these conversations usually do timelines, construction phases, equipment delivery schedules. Dutch Pharma CAPEX…
Read MoreWhat Investors Look for in Life Sciences Leadership Teams
Introduction: A Hard Truth We See in the Dutch Market Let’s start with something we’ve observed repeatedly across the Netherlands life sciences ecosystem. A company can have exceptional science published research, promising data, strong academic backing and still struggle to secure investment. Why? Because investors are not only funding innovation. They are funding the people…
Read MoreHow High-Performing Life Sciences Teams Are Built, Not Found
High Performance is rare and in the Netherlands, It’s Earned If you look at global research, only around 30% of teams are considered truly high performing. In innovation-heavy sectors like Life Sciences, the bar is even higher. Here in the Netherlands, the pressure is tangible. From biotech scale-ups in Leiden to MedTech innovators in Eindhoven…
Read More